Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy
- 18 October 2004
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 6 (12), 1333-1342
- https://doi.org/10.1002/jgm.635
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinomaGene Therapy, 2004
- A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerCancer Gene Therapy, 2002
- Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian CarcinomaThe American Journal of Pathology, 2002
- Many actions of cyclooxygenase‐2 in cellular dynamics and in cancerJournal of Cellular Physiology, 2002
- Adenoviruses in OncologyBioDrugs, 2002
- Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and Its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal CancersMolecular Therapy, 2001
- Thymidine Kinase Gene Therapy for Human Malignant Glioma, Using Replication-Deficient Retroviruses or AdenovirusesHuman Gene Therapy, 2000
- Adenoviral-Mediated Suicide Gene Therapy for Ovarian CancerMolecular Therapy, 2000
- A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancerNature Medicine, 2000
- Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tkMolecular Therapy, 2000